Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Apr;44(4):908-913.
doi: 10.1002/nau.70032. Epub 2025 Mar 12.

A Randomized Controlled Trial of Percutaneous Tibial Nerve Stimulation in the Treatment of Female Sexual Dysfunction

Zhenyue Huang  1 , Sina Mehraban Far  2 , Jonathan Aronov  2 , Arshia Aalami Harandi  1 , Kuemin Hwang  3 , Xiaoyue Zhang  4 , Varun Talanki  1 , Heng Ruan  5 , Tal Meir Cohen  1 , Steven Weissbart  1 , Justina Tam  1 , Jason Kim  1
Affiliations
Randomized Controlled Trial

A Randomized Controlled Trial of Percutaneous Tibial Nerve Stimulation in the Treatment of Female Sexual Dysfunction

Zhenyue Huang et al. Neurourol Urodyn. 2025 Apr.

Abstract

Background: Female sexual dysfunction (FSD) is a prevalent and multifaceted condition affecting women's sexual well-being. This randomized controlled trial aimed to evaluate the efficacy of percutaneous tibial nerve stimulation (PTNS) compared to a validated sham control in the treatment of FSD.

Methods: We conducted a single-center randomized controlled trial. Participants with FSD were recruited and randomly assigned at a 1:1 allocation ratio to either PTNS or a validated sham control using transcutaneous nerve stimulation (TENS). Treatment was performed through weekly 30-min session for 12 weeks total. Sexual function was assessed at baseline, 6 weeks, and 12 weeks primarily using the Female Sexual Function Index (FSFI) questionnaire. Urogenital distress inventory-6 was collected to evaluate for any baseline urinary incontinence/voiding dysfunction. Linear mixed-effect models for longitudinal data were used to compare FSFI scores across different time points. Statistical analysis was performed using SAS 9.4 (SAS Institute Inc. Cary, NC).

Results: In total, 34 PTNS and 31 TENS subjects were included in our final analysis. Overall, 48% (16/34) of PTNS subjects versus 29% (11/33) of TENS subjects were no longer at risk for FSD (FSFI > 26.55) after 12 weekly treatments. Both PTNS and TENS subjects demonstrated similar improvements in FSFI total scores after 12 weeks of treatments. Interestingly, patients who did not present with baseline urogenital distress symptoms reported a statistically significant larger improvement in sexual satisfaction after PTNS treatments as compared to placebo (p = 0.017).

Conclusion: This study demonstrated a sustained efficacy of PTNS in improving sexual function. Specifically, patients who did not have coexisting urinary dysfunction reported significant improvement in sexual satisfaction after PTNS. Our study suggested that PTNS may have a direct neuromodulation effect on sexual dysfunction and may hold promise as a treatment modality for FSD.

Keywords: female sexual dysfunction; neuromodulation; percutaneous tibial nerve stimulation.

PubMed Disclaimer

References

    1. A. H. Clayton and E. M. Valladares Juarez, “Female Sexual Dysfunction,” Medical Clinics of North America 103 (2019): 681–698.
    1. R. E. Nappi, L. Tiranini, E. Martini, D. Bosoni, A. Righi, and L. Cucinella, “Medical Treatment of Female Sexual Dysfunction,” Urologic Clinics of North America 49 (2022): 299–307.
    1. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology, “Female Sexual Dysfunction: ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician‐Gynecologists, Number 213,” Obstetrics & Gynecology 134 (2019): e1–e18.
    1. C. W. Lo, M. Y. Wu, S. S. D. Yang, F. S. Jaw, and S. J. Chang, “Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta‐Analysis,” Toxins 12 (2020): 128.
    1. E. R. Duralde and T. S. Rowen, “Urinary Incontinence and Associated Female Sexual Dysfunction,” Sexual Medicine Reviews 5 (2017): 470–485.

Publication types

LinkOut - more resources